-5%
Brinzolamide (1%)
- Inhibits carbonic anhydrase in the ciliary processes, reducing aqueous humor secretion.
- Peak ocular hypotensive effect: 2-3 hours post-dosing.
Brimonidine Tartrate (0.2%)
- Dual action: reduces aqueous humor production and increases uveoscleral outflow.
- Peak ocular hypotensive effect: 2 hours post-dosing.
Key Benefit: Decreases elevated IOP, a major risk factor in glaucomatous optic nerve damage and visual field loss.
Benozol BR is a fixed combination of:
- Carbonic anhydrase inhibitor (Brinzolamide)
- Alpha-2 adrenergic receptor agonist (Brimonidine Tartrate)
Use:
Reduction of elevated intraocular pressure (IOP) in patients with:
- Open-angle glaucoma
- Ocular hypertension
